Thermo Fisher Scientific (NYSE:TMO) inks an agreement with Eli Lilly (NYSE:LLY) to develop its next-generation sequencing (NGS)-based Oncomine Dx Target Test as a companion diagnostic aimed at identifying suitable NSCLC and thyroid cancer patients for the latter’s RET inhibitor selpercatinib (LOXO-292).
Under the terms of the deal, TMO will retain commercialization rights in all markets and will be responsible for regulatory filings. Financial terms are not disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.